• 

  Cassava Fraud Case Dismissed, Closing a Chapter in Alzheimer’s Drug Saga
• 

  After Two Phase 3 Trial Fails, Cassava Sciences Gives Up On Alzheimer’s Drugs
• 

  Cassava Drug Simufilam Fails First Phase 3 Trial, Halts Second Phase 3 Trial
• 

  After Cassava Fraud Indictment, Questioning the Ethics of Simufilam Trial
• 

  Alzheimer’s Drug Trial Drama: Cassava CEO Resigns After News of Federal Probe
• 

  Former Cassava Advisor Indicted for Fraud, 2 Senior Employees Under Investigation
• 

  Leaked Investigation Into Cassava Alzheimer’s Drug Data Now on Pause
• 

  Cassava’s Simufilam Trial Data Still Under Scrutiny
• 

  Cassava Rebukes Fraud Allegations, Faces Calls to Halt Alzheimer’s Drug Phase III Trials
• 

  Cassava’s Data on Simufilam Looks Promising—Experts Say Too Soon to Know
• 

  Cassava CEO Remi Barbier on New Experimental Alzheimer’s Drug
• 

  Cassava’s Simufilam: Who to Believe—Wall Street or Alzheimer’s Researchers?